Topical autologous blood clot therapy: an introduction and development of consensus panel to guide use in the treatment of complex wound types.


Journal

Wounds : a compendium of clinical research and practice
ISSN: 1943-2704
Titre abrégé: Wounds
Pays: United States
ID NLM: 9010276

Informations de publication

Date de publication:
09 2022
Historique:
entrez: 11 10 2022
pubmed: 12 10 2022
medline: 14 10 2022
Statut: ppublish

Résumé

Complex or hard-to-heal wounds can be acute or chronic; the complexity is based on patient-specific local, systemic, and psychosocial factors. Use of autologous tissue can be a significant adjunct to wound closure. Grafts and flaps are the most common autologous tissue used in wound reconstruction. However, patient factors, wound size, and exposed structures may preclude using these methods as primary or even secondary closure techniques. Alternative autologous tissue therapies include those derived from adipose, epidermis or dermis, bone marrow, and blood. Limitations of these treatment modalities include access-related difficulty, cost, creation of a secondary donor site, use of singular or limited cell types, and sparse or contradictory evidence basis of their efficacy of use. A panel of providers experienced in wound care and surgical wound management was convened to create a series of publications on the use of topical autologous blood clot therapy (TABCT) in the treatment of complex wounds. This publication, the first in a series, provides an evidence basis of the gap between definition and treatment of complex wounds, an overview of the use of autologous therapies in these wounds, and the science behind TABCT. The development of a consensus panel for decision pathways and recommendations for TABCT use in specific complex wound types are also discussed. Subsequent articles will provide consensus recommendations on the use of TABCT in full-thickness wounds with exposed tendon and/or bone and undermining or tunneling wounds, in wounds in patients who are nonsurgical candidates, in those who cannot undergo sharp debridement, in patients with arterial wounds who have been maximally revascularized, and in those with transsphincteric anal fistula. This article provides a foundation of knowledge and describes the plan for consensus panel decision pathways and recommendation development of use of TABCT in the treatment of specific complex wound types.

Identifiants

pubmed: 36219459
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-228

Auteurs

Robert J Snyder (RJ)

Dean, School of Podiatric Medicine and Professor and Director of Clinical Research, Barry University School of Podiatric Medicine, Miami, FL.

Vickie Driver (V)

System Chief, Wound Care, Limb Preservation and Hyperbaric Medicine Centers and Director, Wound Care and Hyperbaric Research, Inova Heart and Vascular Institute, Inova Healthcare System, and Professor at the University of Virginia, School of Medicine, Alexandria, VA.

Windy Cole (W)

Director of Wound Care Research, Kent State University College of Podiatric Medicine, Independence, OH.

Warren S Joseph (WS)

Arizona College of Podiatric Medicine, Midwestern University, Glendale, AZ.

Alez Reyzelman (A)

Professor, California School of Podiatric Medicine at Samuel Merritt University; Co-Director, UCSF Center For Limb Preservation, San Francisco, CA.

John C Lantis II (JC)

Site Chief and Professor of Surgery, Mount Sinai West Hospital and Icahn School of Medicine, New York, NY.

Jarrod Kaufman (J)

Chairman of Surgery, Monmouth Medical Center Southern Campus Hospital and Premier Surgical, Township, NJ.

Thomas Wild (T)

Clinic of Plastic, Hand and Aesthetic Surgery, Burn Center, BG Clinic Bergmannstrost, Halle (Saale), Germany; Medical University Halle, Outpatient and Operating Center, Martin-Luther University, Halle (Saale), Germany; University of Applied Science Anhalt, Institute of Applied Bioscience and Process Management, Head of Education Course "Academic Wound Consultant" Koethen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH